These highlights do not include all the information needed to use PREVACID safely and effectively. See full prescribing information for PREVACID.
PREVACID (lansoprazole) delayed-release capsules, for oral use
PREVACID SoluTab (lansoprazole) delayed-release orally disintegrating tablets, for oral use
Initial U.S. Approval: 1995
INDICATIONS AND USAGE
PREVACID is a proton pump inhibitor (PPI) indicated for:
-
•
-
Short-Term Treatment of Active Duodenal Ulcer ( 1.1)
-
•
-
H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence ( 1.2)
-
•
-
Maintenance of Healed Duodenal Ulcers ( 1.3)
-
•
-
Short-Term Treatment of Active Benign Gastric Ulcer ( 1.4)
-
•
-
Healing of nonsteroidal anti-inflammatory drugs (NSAID)-Associated Gastric Ulcer ( 1.5)
-
•
-
Risk Reduction of NSAID-Associated Gastric Ulcer ( 1.6)
-
•
-
Gastroesophageal Reflux Disease (GERD) ( 1.7)
-
•
-
Maintenance of Healing of Erosive Esophagitis (EE) ( 1.8)
-
•
-
Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome (ZES) ( 1.9)
DOSAGE AND ADMINISTRATION
|
Indication |
Dose |
Frequency |
|
Duodenal Ulcers (1.1, 1.3)
|
|
Short-Term Treatment
|
15 mg
|
Once daily for 4 wks
|
|
Maintenance of Healed
|
15 mg
|
Once daily
|
|
H. pylori Eradication to Reduce Recurrence of Duodenal Ulcer (1.2)
|
|
Triple Therapy:
|
PREVACID
Amoxicillin
Clarithromycin
|
30 mg
1 gram
500 mg
|
Twice daily for 10 or 14 days
|
|
Dual Therapy:
|
PREVACID
Amoxicillin
|
30 mg
1 gram
|
Three times daily for 14 days
|
|
Benign Gastric Ulcer (1.4)
|
|
Short-Term Treatment
|
30 mg
|
Once daily up to 8 wks
|
|
NSAID-associated Gastric Ulcer (1.6)
|
|
Healing
|
30 mg
|
Once daily for 8 wks
|
|
Risk Reduction
|
15 mg
|
Once daily up to 12 wks
|
|
GERD (1.7)
|
|
Short-Term Treatment of Symptomatic GERD
|
15 mg
|
Once daily up to 8 wks
|
|
Short-Term Treatment of EE
|
30 mg
|
Once daily up to 8 wks
|
|
Pediatric (8.4)
|
|
(1 to 11 years of age) Short-Term Treatment of Symptomatic GERD and Short-Term Treatment of EE
|
|
≤ 30 kg
|
15 mg
|
Once daily up to 12 wks
|
|
> 30 kg
|
30 mg
|
Once daily up to 12 wks
|
|
(12 to 17 years of age) Short-Term Treatment of Symptomatic GERD
|
|
Nonerosive GERD
|
15 mg
|
Once daily up to 8 wks
|
|
EE
|
30 mg
|
Once daily up to 8 wks
|
|
Maintenance of Healing of EE (1.8)*
|
15 mg
|
Once daily*
|
|
Pathological Hypersecretory Conditions (i.e., ZES) (1.9)
|
60 mg
|
Once daily
|
*Studied for 12 months
DOSAGE FORMS AND STRENGTHS
Capsules and Tablets: 15 mg and 30 mg. (3)
CONTRAINDICATIONS
Contraindicated in patients with known severe hypersensitivity to any component of the PREVACID formulation. (4)
WARNINGS AND PRECAUTIONS
